Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?
about
Combined Screening for Early Detection of Pre-EclampsiaInnate immunity, decidual cells, and preeclampsiaDrug treatment of hypertension in pregnancyHtrA3 as an early marker for preeclampsia: specific monoclonal antibodies and sensitive high-throughput assays for serum screening.First trimester aneuploidy screening program for preeclampsia prediction in a portuguese obstetric population.The role of the carbohydrate recognition domain of placental protein 13 (PP13) in pregnancy evaluated with recombinant PP13 and the DelT221 PP13 variantLIMK1 regulates human trophoblast invasion/differentiation and is down-regulated in preeclampsia.Protocadherin-12 cleavage is a regulated process mediated by ADAM10 protein: evidence of shedding up-regulation in pre-eclampsia.TNF-R1 as a first trimester marker for prediction of pre-eclampsia.PlGF in a clinical setting of pregnancies at risk of preeclampsia and/or intrauterine growth restriction.First trimester serum placental growth factor and hyperglycosylated human chorionic gonadotropin are associated with pre-eclampsia: a case control study.Eclampsia characteristics and outcomes: a comparison of two eras.Placental Expression Patterns of Galectin-1, Galectin-2, Galectin-3 and Galectin-13 in Cases of Intrauterine Growth Restriction (IUGR).Decreased levels of folate receptor-β and reduced numbers of fetal macrophages (Hofbauer cells) in placentas from pregnancies with severe pre-eclampsia.Mechanisms and management of hypertension in pregnant women.First trimester serum markers to predict preeclampsia.Predictive biomarkers of pre-eclampsia and effectiveness of preventative interventions for the disease.Treatment of preeclampsia: current approach and future perspectives.SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014.Placental Protein 13 Administration to Pregnant Rats Lowers Blood Pressure and Augments Fetal Growth and Venous Remodeling.Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy.HIF1A and MIF as potential predictive mRNA biomarkers of pre-eclampsia: a longitudinal prospective study in high risk population.Correlations between circulating levels of adipokines and anti-angiogenic factors in women with BMI <30 and a late-onset preeclampsia.Can detection of late-onset PE at triage by sflt-1 or PlGF be improved by the use of additional biomarkers?Economic assessment of screening for pre-eclampsia.Recurrence and severity of abnormal pregnancy outcome in patients treated by low-molecular-weight heparin: a prospective pilot study.Early-onset preeclampsia is associated with perinatal mortality and severe neonatal morbidity.Developing a new algorithm for first and second trimester preeclampsia screening in twin pregnancies.Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy studyRenal Interlobar Vein Impedance Index as a First-Trimester Marker Does Not Predict Hypertensive Disorders of PregnancyPrevention of preeclampsia
P2860
Q26801503-42FA566B-7D2B-4835-89C1-2E94AA5E1BA4Q27014127-41E085E6-12C2-4157-AA5E-41F39A539F48Q27014718-6E21D588-FFE1-4B20-9DDD-BDEE57748F19Q31102995-C6005922-C961-43E6-B39E-6520D50422A9Q33758710-A793C98D-FAE3-4D93-B6DA-A6F3356D176EQ33981931-FD1D0A25-486E-4AEF-A425-B05124435446Q34646945-D9D8E203-3914-4E22-947B-4351A758E42AQ34869050-D183E92C-F187-4357-AE09-0973B1310275Q35574857-BA2608E9-EDA8-4E77-8F46-DC011870BF6BQ35974116-F262547F-53AA-48CD-8C50-CBC9F520F5CEQ36204185-D674DBAC-13A0-4776-9447-955C8506FA23Q36829814-9198D5B8-FE9B-4239-977B-DA6C76D81110Q36847097-CB602AAA-7734-4C20-8A8B-0B591866DD56Q36940949-2B48D97C-0B34-4A1E-8DB9-4F1729CAE450Q37103549-5C25B0CE-82CE-4155-BEC1-A9A8AD5347DFQ38020351-A0005D20-4457-4B15-BE19-F4F446675902Q38207099-F9E10737-44AB-439B-B612-60332D21F9BBQ38241124-B87E57E9-F98D-4692-870D-067E76566F3BQ38594110-013C13ED-A239-44E5-8B74-D63DC504A8D0Q38969936-238697CC-92F1-4BBC-A60A-8792F889CB18Q43741719-A34C0809-4CBE-4A87-8092-0F1868C692A2Q46314287-FF235273-D247-440B-BDD2-DC79845DD7F6Q46317860-BFAEB54C-7D8D-4CE0-8F69-898C7CAB7A4AQ46321999-5059A0F8-A081-4AB6-9489-FD5F45E41D87Q46325309-F1A7C389-1A7F-4140-BF19-07A104066526Q47341597-4960592C-3D2B-4647-BDA9-8FB8AE422A36Q47546557-0E877090-11EF-40CC-945F-63B176390129Q50549921-A06B25D2-0847-402B-94F8-67244C23F174Q58035948-E6B3C3E7-33C2-468C-94DA-1F2C7EEA0626Q58205351-C85A0392-99B6-4845-A30E-B1AF90285F74Q58911049-31815E88-BB89-4637-A5F4-ACBD1960000F
P2860
Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pregenesys pre-eclampsia marke ...... tailor preventive strategies?
@en
Pregenesys pre-eclampsia marke ...... tailor preventive strategies?
@nl
type
label
Pregenesys pre-eclampsia marke ...... tailor preventive strategies?
@en
Pregenesys pre-eclampsia marke ...... tailor preventive strategies?
@nl
prefLabel
Pregenesys pre-eclampsia marke ...... tailor preventive strategies?
@en
Pregenesys pre-eclampsia marke ...... tailor preventive strategies?
@nl
P2093
P50
P1433
P1476
Pregenesys pre-eclampsia marke ...... tailor preventive strategies?
@en
P2093
D Williams
K Nicolaides
P Soothill
P356
10.1016/J.PLACENTA.2010.11.022
P478
P577
2010-12-23T00:00:00Z